Meridian Bioscience Provides FY14 Outlook, Reaffirms FY13 Guidance - Quick Facts

(RTTNews) - Meridian Bioscience, Inc., (VIVO) Monday provided guidance for 2014, and reaffirmed its 2013 outlook. For the fiscal year ending September 30, 2014, it expects net sales to be in the range of $203 million to $208 million, and earnings to be between $0.98 per share and $1.03 per share. Analysts expect the company to report earnings of $0.92 per share, on revenues of $205.61 million. Net earnings are expected to increase between about 10 percent and 15 percent from fiscal 2013 to 2014.

The company reaffirmed earnings outlook range of between $0.86 per share to $0.91 per share on net sales of $190 million to $195 million for the full year 2013, with current revenue expectations being near the low end of the range. Analysts expect Meridian to report earnings of $0.82 on revenues of $188.88 million for fiscal 2013.

John Kraeutler, chief executive officer said, "As is the case in fiscal 2013, the primary drivers of our growth will continue to be our illumigene molecular system along with our tests for E. coli, Campylobacter and H. pylori from our diagnostics business. Meridian Life Science is expected to derive its growth from sales of its unique molecular components, such as MyTaq and SensiFAST, plus an expanding position in our industrial customer base in global markets, especially in China."